Most studies investigating the efficacy of GLP-1 analogs are focused on their application in obesity and MASH treatments, thereby leaving a substantial area for exploration concerning their effectiveness in earlier stages of NAFLD, as a preventive measure in MASH development. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.